Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
نویسندگان
چکیده
منابع مشابه
Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
Cytarabine (cytosine arabinoside) is one of the most effective drugs for the treatment of acute myeloid leukemia. The standard dose of cytarabine used to treat this leukemia is 100 mg per square meter. In an attempt to improve the effectiveness of cytarabine against acute myeloid leukemia, a high-dose treatment (3,000 mg per square meter) was introduced into therapy. The side effects of high-do...
متن کاملPancreatitis during therapy of acute myeloid leukemia: cytarabine related?
BACKGROUND Acute pancreatitis in acute myeloid leukemia (AML) has been rarely associated with cytarabine therapy. This report attempts to characterize this toxicity. PATIENTS AND METHODS Criteria for pancreatitis was prospectively defined. Seven patients with pancreatitis were identified from an AML database and a clinical study at two tertiary care centers (n = 134). Their records were retro...
متن کاملHigh-dose cytarabine induction for acute myeloid leukemia.
In a recent article, Bishop et al’ state that high-dose cytarabine has not previously been used as induction for untreated acute myeloid leukemia (AML). In fact, high-dose cytarabine has been used by itself: with am~acrine,~ and with daunorubicin4 in this role. Additionally, doses of cytarabine significantly above those considered standard had previously been used by other groups for initial in...
متن کاملA randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
BACKGROUND We conducted a prospective, multicenter cooperative study to compare two courses of modified intermediate-dose cytarabine (Ara-C) (mIDAC; Ara-C at a dose of 1.0 g/m(2) every 12 hours for 5 days) versus high-dose Ara-C (HDAC; Ara-C at a dose of 2.0 g/m(2) every 12 hours for 5 days) in post-remission therapy for acute myeloid leukemia (AML) to confirm the post-remission antileukemic ef...
متن کاملFacts about FCE (fludarabine, cytarabine, etoposide) in acute myeloid leukemia.
transplant. The authors describe a high rate of morphological complete remissions (75%) and very low rates of treatment-related morbidity and mortality. Also, half of the patients achieving a complete remission successfully received an allogeneic transplant and pretransplant use of FCE did not increase transplant-related early mortality. Despite these encouraging early outcomes, several concern...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Experimental Hematology & Oncology
سال: 2013
ISSN: 2162-3619
DOI: 10.1186/2162-3619-2-20